Format
Sort by
Items per page

Send to

Choose Destination

Links from Books

Items: 1 to 20 of 88

1.

Combination therapy - deferasirox and deferoxamine - in thalassemia major patients in emerging countries with limited resources.

Arandi N, Haghpanah S, Safaei S, Zahedi Z, Ashrafi A, Eatemadfar P, Zarei T, Radwan AH, Taher AT, Karimi M.

Transfus Med. 2015 Feb;25(1):8-12. doi: 10.1111/tme.12188. Epub 2015 Mar 19.

PMID:
25801075
2.

Efficacy and safety of a novel combination of two oral chelators deferasirox/deferiprone over deferoxamine/deferiprone in severely iron overloaded young beta thalassemia major patients.

Elalfy MS, Adly AM, Wali Y, Tony S, Samir A, Elhenawy YI.

Eur J Haematol. 2015 Nov;95(5):411-20. doi: 10.1111/ejh.12507. Epub 2015 Mar 27.

PMID:
25600572
3.

Prevalence and distribution of iron overload in patients with transfusion-dependent anemias differs across geographic regions: results from the CORDELIA study.

Aydinok Y, Porter JB, Piga A, Elalfy M, El-Beshlawy A, Kilinç Y, Viprakasit V, Yesilipek A, Habr D, Quebe-Fehling E, Pennell DJ.

Eur J Haematol. 2015 Sep;95(3):244-53. doi: 10.1111/ejh.12487. Epub 2015 Jan 8.

PMID:
25418187
4.

Non-invasive prenatal diagnostic testing for β-thalassaemia using cell-free fetal DNA and next generation sequencing.

Xiong L, Barrett AN, Hua R, Tan TZ, Ho SS, Chan JK, Zhong M, Choolani M.

Prenat Diagn. 2015 Mar;35(3):258-65. doi: 10.1002/pd.4536. Epub 2014 Dec 29.

PMID:
25400264
5.

Hepatocellular carcinoma in thalassaemia: an update of the Italian Registry.

Borgna-Pignatti C, Garani MC, Forni GL, Cappellini MD, Cassinerio E, Fidone C, Spadola V, Maggio A, Restivo Pantalone G, Piga A, Longo F, Gamberini MR, Ricchi P, Costantini S, D'Ascola D, Cianciulli P, Lai ME, Carta MP, Ciancio A, Cavalli P, Putti MC, Barella S, Amendola G, Campisi S, Capra M, Caruso V, Colletta G, Volpato S.

Br J Haematol. 2014 Oct;167(1):121-6. doi: 10.1111/bjh.13009. Epub 2014 Jul 3.

PMID:
24992281
6.

Modified activin receptor IIB ligand trap mitigates ineffective erythropoiesis and disease complications in murine β-thalassemia.

Suragani RN, Cawley SM, Li R, Wallner S, Alexander MJ, Mulivor AW, Gardenghi S, Rivella S, Grinberg AV, Pearsall RS, Kumar R.

Blood. 2014 Jun 19;123(25):3864-72. doi: 10.1182/blood-2013-06-511238. Epub 2014 May 2.

7.

Bisphosphonates in the management of thalassemia-associated osteoporosis: a systematic review of randomised controlled trials.

Giusti A.

J Bone Miner Metab. 2014 Nov;32(6):606-15. doi: 10.1007/s00774-014-0584-8. Epub 2014 Apr 21. Review.

PMID:
24748165
8.

Guidelines for the Management of Non Transfusion Dependent Thalassaemia (NTDT) [Internet].

Taher A, Vichinsky E, Musallam K, Cappellini MD, Viprakasit V; Weatherall D, editor.

Nicosia, Cyprus: Thalassaemia International Federation; 2013.

9.

An activin receptor IIA ligand trap corrects ineffective erythropoiesis in β-thalassemia.

Dussiot M, Maciel TT, Fricot A, Chartier C, Negre O, Veiga J, Grapton D, Paubelle E, Payen E, Beuzard Y, Leboulch P, Ribeil JA, Arlet JB, Coté F, Courtois G, Ginzburg YZ, Daniel TO, Chopra R, Sung V, Hermine O, Moura IC.

Nat Med. 2014 Apr;20(4):398-407. doi: 10.1038/nm.3468. Epub 2014 Mar 23.

PMID:
24658077
10.

Modulators of erythropoiesis: emerging therapies for hemoglobinopathies and disorders of red cell production.

Breda L, Rivella S.

Hematol Oncol Clin North Am. 2014 Apr;28(2):375-86. doi: 10.1016/j.hoc.2013.12.001. Epub 2014 Jan 18. Review.

11.

A 1-year randomized controlled trial of deferasirox vs deferoxamine for myocardial iron removal in β-thalassemia major (CORDELIA).

Pennell DJ, Porter JB, Piga A, Lai Y, El-Beshlawy A, Belhoul KM, Elalfy M, Yesilipek A, Kilinç Y, Lawniczek T, Habr D, Weisskopf M, Zhang Y, Aydinok Y; CORDELIA study investigators..

Blood. 2014 Mar 6;123(10):1447-54. doi: 10.1182/blood-2013-04-497842. Epub 2014 Jan 2.

12.

Bone marrow transplantation for thalassemia from alternative related donors: improved outcomes with a new approach.

Gaziev J, Marziali M, Isgrò A, Sodani P, Paciaroni K, Gallucci C, Andreani M, Testi M, De Angelis G, Alfieri C, Cardarelli L, Ribersani M, Armiento D, Lucarelli G.

Blood. 2013 Oct 10;122(15):2751-6. doi: 10.1182/blood-2013-07-513473. Epub 2013 Aug 20.

13.

Minihepcidins prevent iron overload in a hepcidin-deficient mouse model of severe hemochromatosis.

Ramos E, Ruchala P, Goodnough JB, Kautz L, Preza GC, Nemeth E, Ganz T.

Blood. 2012 Nov 1;120(18):3829-36. doi: 10.1182/blood-2012-07-440743. Epub 2012 Sep 18.

14.

Noninvasive prenatal diagnosis of monogenic diseases by targeted massively parallel sequencing of maternal plasma: application to β-thalassemia.

Lam KW, Jiang P, Liao GJ, Chan KC, Leung TY, Chiu RW, Lo YM.

Clin Chem. 2012 Oct;58(10):1467-75. Epub 2012 Aug 15.

15.

Toward optimizing the use of deferasirox: potential benefits of combined use with deferoxamine.

Grady RW, Galanello R, Randolph RE, Kleinert DA, Dessi C, Giardina PJ.

Haematologica. 2013 Jan;98(1):129-35. doi: 10.3324/haematol.2012.070607. Epub 2012 Aug 8.

16.

Hypercoagulability in non-transfusion-dependent thalassemia.

Cappellini MD, Musallam KM, Poggiali E, Taher AT.

Blood Rev. 2012 Apr;26 Suppl 1:S20-3. doi: 10.1016/S0268-960X(12)70007-3. Review.

PMID:
22631037
17.

Deferasirox reduces iron overload significantly in nontransfusion-dependent thalassemia: 1-year results from a prospective, randomized, double-blind, placebo-controlled study.

Taher AT, Porter J, Viprakasit V, Kattamis A, Chuncharunee S, Sutcharitchan P, Siritanaratkul N, Galanello R, Karakas Z, Lawniczek T, Ros J, Zhang Y, Habr D, Cappellini MD.

Blood. 2012 Aug 2;120(5):970-7. doi: 10.1182/blood-2012-02-412692. Epub 2012 May 15.

18.

A national registry of haemoglobinopathies in Greece: deducted demographics, trends in mortality and affected births.

Voskaridou E, Ladis V, Kattamis A, Hassapopoulou E, Economou M, Kourakli A, Maragkos K, Kontogianni K, Lafioniatis S, Vrettou E, Koutsouka F, Papadakis A, Mihos A, Eftihiadis E, Farmaki K, Papageorgiou O, Tapaki G, Maili P, Theohari M, Drosou M, Kartasis Z, Aggelaki M, Basileiadi A, Adamopoulos I, Lafiatis I, Galanopoulos A, Xanthopoulidis G, Dimitriadou E, Mprimi A, Stamatopoulou M, Haile ED, Tsironi M, Anastasiadis A, Kalmanti M, Papadopoulou M, Panori E, Dimoxenou P, Tsirka A, Georgakopoulos D, Drandrakis P, Dionisopoulou D, Ntalamaga A, Davros I, Karagiorga M; Greek Haemoglobinopathies Study Group..

Ann Hematol. 2012 Sep;91(9):1451-8. Epub 2012 Apr 19.

PMID:
22526366
19.

Non-invasive prenatal diagnosis of beta-thalassemia and sickle-cell disease using pyrophosphorolysis-activated polymerization and melting curve analysis.

Phylipsen M, Yamsri S, Treffers EE, Jansen DT, Kanhai WA, Boon EM, Giordano PC, Fucharoen S, Bakker E, Harteveld CL.

Prenat Diagn. 2012 Jun;32(6):578-87. doi: 10.1002/pd.3864. Epub 2012 Apr 20.

PMID:
22517437
20.

Deferasirox for up to 3 years leads to continued improvement of myocardial T2* in patients with β-thalassemia major.

Pennell DJ, Porter JB, Cappellini MD, Chan LL, El-Beshlawy A, Aydinok Y, Ibrahim H, Li CK, Viprakasit V, Elalfy MS, Kattamis A, Smith G, Habr D, Domokos G, Roubert B, Taher A.

Haematologica. 2012 Jun;97(6):842-8. doi: 10.3324/haematol.2011.049957. Epub 2012 Jan 22.

Supplemental Content

Support Center